File downloaded on 2026-10-31
Source URL: https://medicines.health.europa.eu/veterinary/en/600000000433

Credelio Plus 225 mg + 8.44 mg - Chewable tablet

Authorised

- Lotilaner
- Milbemycin oxime

Product identification

Medicine name:
Credelio Plus 225 mg + 8.44 mg - Chewable tablet

Active substance:
Lotilaner
Milbemycin oxime

Target species:
Dog

Route of administration:
Oral use

Product details

Active substance and strength:
Lotilaner
Presentation_strength:225 mg Reference:In house Index:0
Milbemycin oxime

Presentation_strength:8.44 mg Reference:Ph. Eur. Index:1

Pharmaceutical form:

Chewable tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QP54AB51

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Available in:

Belgium , Bulgaria , Croatia , Cyprus , Czechia , Estonia , France , Greece , Hungary , Italy , Latvia , Lithuania , Netherlands , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , United Kingdom (Northern Ireland)

Package description:

Packaging:Blister (alu), Package_size:3 tablets

Packaging:Blister (alu), Package_size:1 tablet

Packaging:Blister (alu), Package_size:6 tablets

Packaging:Blister (alu), Package_size:18 tablets

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Fixed combination application (Article 13b of Directive No 2001/82/EC)

Marketing authorisation holder:

Elanco GmbH

Marketing authorisation date:
14/04/2021

Manufacturing sites for batch release:
Elanco France S.A.S.

Responsible authority:
European Commission

Authorisation number:
This information is not available for this product.

Date of authorisation status change:
14/04/2021

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)
Published on: 9/01/2024
Updated on: 14/03/2026
Download

ema-puar-v5325-credelioplus-vra0000261365-en.pdf

ema-puar-credelio-plus-v-5325-par-en.pdf

ema-puar-credelio-plus-v-5325-var-vra-0005-en.pdf